Check this box if no longer subject to boligations may continue. See instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB Number: Estimated aver hours per resp Image: Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See instruction 10. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Image: Securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See instruction 10. 1. Name and Address of Reporting Person* Malca Yonatan (Last) (First) (Middle) 2. Issuer Name and Ticker or Trading Symbol Entera Bio Ltd. [ENTX] 5. Relationship of Reporting Person (Check all applicable). Windley 3. Date of Earliest Transaction (Month/Day/Year) 01/15/2025 Director Officer (give title below)	verage burden esponse: 0.5 son(s) to Issuer 10% Owner Other (specify below)
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATE ENERT OF CHARGES IN DEPENDENCIAL OWNERSHIP Filed pursuant to Form 5 obligations may continue. See Instruction 1(b). Estimated aver hours per resp Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. S. Relationship of Reporting Person* 1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Persor (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 01/15/2025 5. Relationship of Reporting Persor (Check all applicable) WINRAY BUILDING, FIFTH FLOOR MINRAY BUILDING, FIFTH FLOOR All of Carliest Transaction (Month/Day/Year) 01/15/2025	verage burden esponse: 0.5 son(s) to Issuer 10% Owner Other (specify below)
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Name and Address of Reporting Person* Alaca Yonatan Last) (First) (Middle) KIRYAT HADASSAH MINRAV BUILDING, FIFTH FLOOR 	10% Owner Other (specify below)
Malca Yonatan Entera Bio Ltd. [ENTX] (Check all applicable) (Last) (First) (Middle) KIRYAT HADASSAH 01/15/2025 Officer (give title below)	10% Owner Other (specify below)
(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) below) KIRYAT HADASSAH 01/15/2025 01/15/2025	below)
MINRAV BUILDING, FIFTH FLOOR	(Obsels Andlershie
(Street) JERUSALEM L3 9112002 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (CLine)	orting Person
(City) (State) (Zip)	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
Date Execution Date, Transaction Disposed Of (D) (Instr. 3, 4 and Securities Form: I	
Code V Amount (A) or (D) Price Transaction(s) (Instr. 3 and 4)	(Instr. 4)
Ordinary Shares, par value NIS 0.0000769 per share $01/15/2025$ $A^{(1)}$ $8,216$ A $\$0$ $47,259$ I	D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)	
Derivative Security (Instr. 3) Conversion or Exercise Derivative Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) of Derivative Security Acquired Expiration Date (Month/Day/Year) of Securities Underlying Derivative Security (Instr. 3) Derivative Security (Instr.	10. 0wnership Form: of Indirect Direct (D) or Indirect (I) (Instr. 4) (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares	
Stock Option (right to buy)01/15/202501/15/2025A28,509(2)Ordinary Shares, par value NIS oper share28,509\$028,509	D

Explanation of Responses:

1. The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.

2. These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.

/s/ Dana Yaacov-Garbeli,	
Attorney-in-Fact	01/17/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.